ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Erwinaze is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with acute lymphoblastic leukemia (ALL) who have developed an allergy to E. coli-derived asparaginase. Erwinaze is sometimes prescribed off-label to treat lymphoma. Erwinaze is also referred to by its drug name, asparaginase Erwinia chrysanthemi.
Erwinaze is a member of a class of drugs called antineoplastic and immunomodulating agents. Erwinaze is believed to work by lowering the levels of asparagine in your body, a substance the cancer cells need to survive.
How do I take it?
Prescribing information states that Erwinaze is injected into a muscle several times a week.
Erwinaze comes in the form of an injectable solution.
The FDA-approved label for Erwinaze lists common side effects including inflammation of the pancreas (pancreatitis), high blood levels of liver enzymes (abnormal transaminases and bilirubin), blood clotting, bleeding (hemorrhage), nausea, vomiting, and high blood sugar (hyperglycemia).
Rare but serious side effects listed for Erwinaze include severe allergic reaction including anaphylaxis, severe inflammation of the pancreas, glucose intolerance, blood clots, and hemorrhage.
For more details about this treatment, visit:
Erwinaze — RxList